Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications B Cells, DC Cells, NK Cells, Other, Treg Cells

Publication Date: September 7, 2023

Extracellular Vesicles from Immune Cells: A Biomedical Perspective

Small extracellular vesicles (sEV) are released by essentially every type of immune cell, and their cargo reflects the biology of the cell of origin. This review organizes the literature by cell group: neutrophils, eosinophils, basophils, mast cells and NK cells; dendritic cells, macrophages, myeloid-derived suppressor cells and B cells; and CD8+, CD4+, regulatory and follicular helper T cells. Vesicles of 50 to 150 nm carry proteins, lipids and miRNAs that can promote or dampen inflammation, kill tumor cells, transfer antigen or suppress T cells. Examples include cytotoxic NK-derived sEV, CD73-bearing Treg and CD8+ T cell sEV, and MDSC sEV that ameliorated colitis and arthritis in mice.…

Download Now →

Author: María José Moya-Guzmán, Javiera de Solminihac +5 more

Publications CAR T Cells

Publication Date: September 5, 2023

Promises and challenges of a decentralized CAR T-cell manufacturing model

Point-of-care manufacturing of autologous CAR T cells within academic healthcare systems is presented as a way to widen patient access and cut costs relative to the centralized commercial model, provided quality can be standardized. Commercial products total nearly $500,000 and patients may wait up to 3 weeks for a manufacturing slot. Decentralized production can shorten manufacturing to 7-10 days instead of 14 and may cost as little as $35,000 when a sponsor supplies the vector. Closed automated platforms such as CliniMACS Prodigy and Cocoon support this model. Main hurdles are GMP vector supply, trained staff, quality control, facilities and financing.

Download Now →

Author: Manan Shah, Ashley Krull +3 more

Publications TIL Cells G-Rex®6 Well Plate

Publication Date: September 4, 2023

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

Adding an oncolytic adenovirus that encodes a variant IL-2 (Ad5/3-E2F-d24-vIL2, also called TILT-452) to autologous tumor-infiltrating lymphocytes improved cytotoxic activity against advanced ovarian cancer. Tumor digests from twelve patients, mostly stage IVB, were co-cultured with autologous TILs and virus. Real-time impedance measurement showed consistent cancer cell killing in all samples except one, compared with TILs alone. In a patient-derived xenograft mouse model, the combination gave the best tumor control, with all treated animals responding until day 12, and raised granzyme B in CD4+ T, CD8+ T and NK cells. Regulatory T cells also increased in these tumors. The sample number w…

Download Now →

Author: D. C. A. Quixabeira, E. Jirovec +15 more

Publications NK Cells G-Rex®6 Well Plate

Publication Date: August 30, 2023

Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function

Expanding human NK cells first with K562 feeder cells carrying membrane-bound IL-21 and then with feeders carrying membrane-bound IL-15 combined high yield with strong antitumor function. Purified NK cells from healthy donors were stimulated with irradiated feeders on day 0 and day 10 and tested on day 20. Feeders with mbIL21 alone gave 15,000- to 700,000-fold expansion versus about 1,000- to 15,000-fold with mbIL15 alone, but weaker antitumor activity by every measure except ADCC. The mbIL21-then-mbIL15 sequence gave far higher yields than mbIL15 alone, killed tumor lines resistant to fresh NK cells, and matched mbIL15-only NK cells in the Raji lymphoma and RPMI-8226 myeloma xenograft mo…

Download Now →

Author: Caimei Zhang, Siddhant Kadu +13 more

Publications NK Cells

Publication Date: August 29, 2023

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

Messenger RNA delivered in lipid nanoparticles can turn expanded natural killer cells into functional CAR-NK cells without viral vectors. NK cells isolated from donor blood were expanded more than 8000-fold on K562 feeder cells expressing 4-1BB ligand and membrane-bound IL-21, then transfected with CD19-CAR or BCMA-CAR mRNA-LNPs, yielding 78.8% and 95.3% CAR-positive cells. The CAR-NK cells killed myeloma lines (RPMI8226, MM1S) and leukemia lines (Daudi, Nalm-6) and secreted more IFN-gamma and Granzyme B than unmodified NK cells. In NSG mice carrying Nalm-6 leukemia, CD19-CAR-NK cells, injected four times, blocked tumor growth significantly more than unmodified NK cells by day 15.

Download Now →

Author: Vita Golubovskaya, John Sienkiewicz +8 more

Publications T-Cells G-Rex®100M-CS, G-Rex®24 Well Plate, G-Rex®500M-CS, G-Rex®6 Well Plate, G-Rex®6M Well Plate

Publication Date: August 23, 2023

Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo

A good manufacturing practice-compliant, scalable process corrected the CD40LG gene in human CD4+ T cells by Cas9 ribonucleoprotein editing with an integrase-defective lentiviral vector donor template, shortening the protocol from 21 to 13 days. Delivering the vector at day 2 before electroporation, together with LentiBoost, gave optimal editing efficiency, and immunomagnetic enrichment of LNGFR-positive cells on day 6 produced a nearly pure product with 46-fold cumulative growth. Patient cells were edited with similar or better efficiency and kept stem cell memory and central memory phenotypes. Edited cells engrafted in NSG mice with stable editing in blood, bone marrow and spleen. At fu…

Download Now →

Author: Claudia Asperti, Daniele Canarutto +18 more

Publications CAR T Cells, Other

Publication Date: August 22, 2023

How can Cytokine-induced killer cells overcome CAR-T cell limits

Cytokine-induced killer (CIK) cells offer a practical alternative to CAR-T cells for patients who cannot access CAR-T therapy, because they avoid viral-vector engineering and can be made in local academic GMP facilities. This review compares the two platforms. CAR-T therapy faces high cost, centralized manufacturing and CRS/ICANS toxicity, whereas CIK cells kill tumors in an MHC-unrestricted manner via NKG2D and rarely cause GvHD. Reagent costs are estimated below €5,000 per batch, and 30 ml of blood can yield enough cells for repeated treatment. G-Rex® expansion gave a 752-fold increase. The authors propose CIK cells alongside, not instead of, CAR-T cells.

Download Now →

Author: Elisa Cappuzzello, Emilia Vigolo +4 more

Application Notes CAR T Cells, NK Cells

Publication Date: July 28, 2023

CAR NK-92 cell–mediated depletion of residual TCR+ cells

Co-culturing gene-edited CAR T cells with irradiated CD3-specific CAR NK-92 cells during expansion stripped residual T cell receptor-positive cells down to below 0.01 per cent, a 45-fold improvement on magnetic separation. Four CD3- or TCR-directed CAR constructs were knocked into the AAVS1 locus of NK-92 cells, and three killed more than 80 per cent of target cells within four hours at the highest ratio while sparing edited cells. Run in G-Rex® 6-well plates from day 5, two spaced co-cultures left 0.026 and 0.007 per cent contaminating cells on day 14 against 3.1 per cent for magnetic separation, roughly tripled yield, and preserved cytotoxicity and phenotype.

Download Now →

Author: Jonas Kath, Weijie Du +12 more

Publications CAR T Cells G-Rex®100M, G-Rex®24 Well Plate, G-Rex®6 Well Plate

Publication Date: June 26, 2023

Homology‑independent targeted insertion (HITI) enables guided CAR knock‑in and efficient clinical scale CAR‑T cell manufacturing

Homology-independent targeted insertion (HITI) with CRISPR/Cas9 and nanoplasmid DNA placed an anti-GD2 CAR into the TRAC locus of primary human T cells and, on average, gave about threefold higher CAR-T cell yields than an HDR template with comparable insertion rates. Adding methotrexate-driven CEMENT selection of a DHFR-FS marker from day 3 raised purity to 86.6–91.4%, and at day 14 enriched cultures reached 80–85% CAR-positive cells. Clinical-scale runs with three donors produced doses of 5.5 × 10^8 to 3.6 × 10^9 CAR-positive T cells in a 14-day process. Average on-target copy number was 1.08, no off-target editing was detected, and knock-in cells matched virally transduced cells in phe…

Download Now →

Author: Hyatt Balke-Want, Vimal Keerthi +15 more

Publications γδ T

Publication Date: June 16, 2023

Cord blood–derived Vδ2+ and Vδ2− T cells acquire differential cell state compositions upon in vitro expansion

Cord blood γδ T cells expanded far better than adult peripheral blood γδ T cells in a feeder-based rapid expansion protocol, and single-cell sequencing showed that their Vδ2− and Vδ2+ subsets follow different differentiation paths. Cord blood γδ T cells were stimulated with irradiated PBMCs and EBV-transformed feeder cells, with IL-2, IL-15 and IL-21, and reached an average 2.5 × 10^6-fold expansion in 3 weeks, versus minimal expansion of peripheral blood cells at day 14. Cells developed into cytotoxic, tissue-resident memory precursor-like and antigen-presenting-like states. Most Vδ1+ and Vδ3+ clones were biased toward cytotoxic cells, whereas Vδ2+ clones, especially Vγ9+Vδ2+, showed a m…

Download Now →

Author: Jeremy Wee Kiat Ng, Kar Wai Tan +12 more

Publications TCR T Cells, TIL Cells G-Rex®10, G-Rex®100M

Publication Date: June 15, 2023

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity

Loss of CD58 on melanoma cells lets tumors escape T cell attack, and the same loss raises PD-L1 through the shared stabilizer CMTM6. In co-cultures of patient-derived melanoma cells with autologous TILs, CD58 knockout reduced killing and IFN-γ release, while re-expressing either CD58 isoform restored both; blocking CD2 or CD58 prevented the rescue. In partly humanized mice, CD58-knockout tumors showed no responders among eight animals given TIL transfer and about 100-fold fewer CD8+ TILs. A genome-wide CRISPR screen and IP-mass spectrometry identified CMTM6 as a CD58 binding partner; CD58 and PD-L1 compete for CMTM6, so CD58 loss stabilizes PD-L1 and reduces its lysosomal degradation. An…

Download Now →

Author: Patricia Ho, Johannes C. Melms +31 more

Publications TCR T Cells, TIL Cells G-Rex®24 Well Plate

Publication Date: May 31, 2023

Cell surface marker- based capture of neoantigen- reactive CD8+ T- cell receptors from metastatic tumor digests

Sorting CD8+ tumor-infiltrating lymphocytes that co-express CD39, PD-1 and TIGIT ("triple positive" TIL) offers a rapid way to capture neoantigen-reactive T-cell receptors directly from metastatic epithelial tumor digests. Clone frequencies in the sorted population correlated strongly with a single-cell transcriptomic neoantigen-reactive state. Of 120 unique CDR3β sequences from five tumors, 39 were already known or met criteria for reconstruction, and reconstruction and testing showed that at least 39.5% of the sorted-population TCRs were neoantigen-reactive or tumor-reactive. After rapid expansion, however, reactive clones were lost or functionally impaired: expanded cells from three of…

Download Now →

Author: Praveen D Chatani, Frank J Lowery +13 more